BIOSTATISTICS IN CLINICAL TRIALS
Kate Francis, Biostatistician (Snr Research Officer)
Murdoch Children’s Research Institute &
Honorary Research Fellow,
Department of Paediatrics, University of Melbourne &
Affiliate Biostatistician,
The Royal Children’s Hospital,
Melbourne, Australia
RESEARCHER PROFILE
Filmed in Melbourne, Australia | July 2025
Kate Francis is a biostatistician with the Murdoch Children’s Research Institute (MCRI), an Honorary (Senior Fellow) within Department of Paediatrics, the University of Melbourne and Affiliate biostatistician with Royal Children’s Hospital in Narrm (Melbourne), Australia.
As a biostatistician working in research and clinical settings, she plays a vital role in ensuring all projects adhere to best practice guidelines and are transparently reported. She has served as the lead statistician for the analysis of clinical trials across a broad range of subject areas, including neonatal resuscitation, BCG for allergy and infection, convulsive status epilepticus and her work has been published in the top journals such as The New England Journal of Medicine, JAMA, and The Lancet. Most recently she was awarded the 2025 Excellence in Trial Statistics Award for her work on the PLUSS trial.
Kate is also an expert in the measurement of adolescent health behaviours, determinants, and outcomes and this was recognised with her invitation to be a commissioner for the second Lancet Commission on Adolescent Health and Wellbeing which was recently released at the 2025 World Health Assembly meeting.
Kate believes in the importance of gender equity, diversity, and inclusion and was key team member in helping MCRI achieve bronze accreditation in the Science in Australia Gender Equity (SAGE) program.
Source: Supplied
-
Pathogenicity, modelling & treatment of inherited retinal Stargardt disease
Dr Di Huang is a Research Associate at the Lions Eye Institute (LEI), working with A/Professor Fred Chen and Dr Sam McLenachan. Her research focuses on developing a robust platform of retinal pigment epithelium cells and retinal organoids derived from patient-specific induced pluripotent stem cells to model inherited retinal diseases, particularly Stargardt disease (STGD1).
-
Genetic disease research imitating function and architecture of organs
Professor Wolvetang was among the first to bring the first human embryonic stem cells to Queensland, with his Wolvetang Group at the AIBN now renowned for its work with organoids: growing them, studying them, and using them to try and understand diseases and human development.
Using cutting edge technology, Professor Wolvetang designs and grows organoids both for their own work and for labs across the country, coaxing pluripotent stem cells or tissue samples into 3D structures that mimic the function and architecture of real brains, livers, kidneys, spinal cords, and intestines.
-
CASE STUDY Next Generation Condom Contraception
Eudaemon Technologies, an early-stage medtech company with a focus on sexual reproductive health, is developing a hydrogel condom to address the need for a better feeling, next generation condom, with the potential to improve user experience and address issues with traditional latex condoms.
“Over 1 million STI’s being diagnosed every day and up to 120 million unplanned pregnancies every year result in a $60 billion health burden across the globe”, says Co-Founder and Executive Director of Operations, Dr Simon Cook.
Formed in 2018, the company focuses on developing tough hydrogels as an alternative to address issues with odour, colour, and taste commonly associated with latex condoms. This technology can be loaded with small molecule drugs for flavours or anti-STI compounds, and was developed in response to a grant from the Bill and Melinda Gates Foundation to address unplanned pregnancies and STIs.
